Victory Capital Management
RLMD icon

Victory Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Victory Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.6K Buy
+10,637
New +$74.3K ﹤0.01% 2357

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management's RLMD Position: Q2 2026 in Review

Victory Capital Management opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 10,637 shares worth $73.6K. The stake represents ﹤0.01% of the portfolio and ranks #2357 among its holdings.

126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Victory Capital Management held 10,637 shares of Relmada Therapeutics worth $73.6K as of Q2 2026.
  • Relmada Therapeutics was a new Victory Capital Management position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2357 holding.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.